Sirolimus-eluting coronary stent - Meril Life Sciences

Drug Profile

Sirolimus-eluting coronary stent - Meril Life Sciences

Alternative Names: BioMime; BioMime Aura

Latest Information Update: 04 Jun 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Meril Life Sciences
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action Immunosuppressants; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 24 May 2014 Meril Life Science plans a phase IV trial for Coronary artery disease in Europe and Brazil (NCT02112981, ISRCTN06697555)
  • 01 Mar 2011 Meril Life Science completes a phase IV trial for Coronary artery disease in India (NCT01507519)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top